Biopharmaceutical company ASC Therapeutics disclosed on Tuesday that it will co-develop the first in-vivo gene therapy for Maple Syrup Urine Disease (MSUD) in partnership with the University of Massachusetts Medical School (UMMS).
MSUD is reportedly a severe genetic disease with liver transplantation as the only treatment currently available. The rare genetic disorder affects the degradation of the branched-chain amino acids (BCAA) leucine, isoleucine and valine and their ketoacid derivatives.
Led by Guangping Gao, PhD, director of the Horae Gene Therapy Center at UMMS and Dan Wang, PhD, assistant professor of RNA therapeutics, ASC will develop multiple animal models for MSUD, as well as conduct pre-clinical testing using animal models and proprietary AAV constructs.
In conjunction, ASC Therapeutics receives an exclusive option on the selected constructs and intellectual property resulting from this partnership.
The partnership will jointly conduct further IND-enabling studies, regulatory and manufacturing activities to obtain US FDA's IND clearance and advance this programme into clinical stage.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT